Erratum zu: FOLFIRINOX beim duktalen Adenokarzinom des PankreasErratum to: FOLFIRINOX for pancreatic ductal adenocarcinoma

被引：0
|
作者：
Hakan Alakus
Michael Korenkov
Fabian Kütting
Christiane Bruns
机构：
[1] Universitätsklinikum Köln (AöR),Klinik und Poliklinik für Allgemein‑, Viszeral
[2] Universitätsklinikum Köln, und Tumorchirurgie
来源：
Der Onkologe | 2019年 / 25卷 / 8期
关键词：
D O I：
10.1007/s00761-019-0615-0
中图分类号：
学科分类号：
摘要：
Erratum zu:
引用
收藏
页码：728 / 728
相关论文
共 50 条
  • [1] FOLFIRINOX beim duktalen Adenokarzinom des PankreasFOLFIRINOX for pancreatic ductal adenocarcinoma
    Hakan Alakus
    Michael Korenkov
    Fabian Kütting
    Christiane Bruns
    Der Onkologe, 2019, 25 (8): : 726 - 727
  • [2] Pathologische Aufbereitung beim duktalen Adenokarzinom des Pankreas – was gibt es Neues?Pathological processing in pancreatic ductal adenocarcinoma—What is new?
    Johanna Munding
    Andrea Tannapfel
    Der Chirurg, 2022, 93 (5): : 453 - 460
  • [3] FOLFIRINOX for locally advanced and metastatic pancreatic ductal adenocarcinoma
    Hisai, Hiroyuki
    Tamaki, Sakurai
    Yuuki, Ikeda
    Yutaka, Koshiba
    Masafumi, Sato
    Ryosuke, Kawasaki
    Hiroshi, Gyobu
    Etsu, Miyazaki
    Tasuku, Hirako
    Shogo, Miura
    ANNALS OF ONCOLOGY, 2015, 26 : 120 - 120
  • [4] Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma
    Thoma C.
    Nature Reviews Gastroenterology & Hepatology, 2019, 16 (3) : 140 - 140
  • [5] Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma
    McIntyre, Caitlin A.
    Cohen, Noah A.
    Goldman, Debra A.
    Gonen, Mithat
    Sadot, Eran
    O'Reilly, Eileen M.
    Varghese, Anna M.
    Yu, Kenneth H.
    Balachandran, Vinod P.
    Soares, Kevin C.
    D'Angelica, Michael, I
    Drebin, Jeffrey A.
    Kingham, T. P.
    Allen, Peter J.
    Wei, Alice C.
    Jarnagin, William R.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (03) : 425 - 436
  • [6] FOLFIRINOX for Pancreatic Ductal Adenocarcinoma (vol 25, pg 726, 2019)
    Alakus, Hakan
    Korenkov, Michael
    Kuetting, Fabian
    Bruns, Christiane
    ONKOLOGE, 2019, 25 (08): : 728 - 728
  • [7] MECHANISTIC EXAMINATION OF THE FOLFIRINOX CHEMOTHERAPEUTIC DRUG REGIMEN ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS
    Byrne, E.
    Chaudhuri, Roy T.
    Lin, Q.
    Vaidya, T.
    Trueman, S.
    Straubinger, N.
    Straubinger, R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S21 - S21
  • [8] Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX
    Hoehn, Philipp
    Braumann, Chris
    Noepel-Duennebacke, Stefanie
    Munding, Johanna
    Uhl, Waldemar
    Luu, Andreas Minh
    VISCERAL MEDICINE, 2021, 37 (02) : 149 - 153
  • [9] Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation
    Neyaz, Azfar
    Tabb, Elisabeth S.
    Shih, Angela
    Zhao, Qing
    Shroff, Stuti
    Taylor, Martin S.
    Rickelt, Steffen
    Wo, Jennifer Y.
    Fernandez-del Castillo, Carlos
    Qadan, Motaz
    Hong, Theodore S.
    Lillemoe, Keith D.
    Ting, David T.
    Ferrone, Cristina R.
    Deshpande, Vikram
    HISTOPATHOLOGY, 2020, 77 (01) : 35 - 45
  • [10] FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
    Moorcraft, Sing Yu
    Khan, Khurum
    Peckitt, Clare
    Watkins, David
    Rao, Sheela
    Cunningham, David
    Chau, Ian
    CLINICAL COLORECTAL CANCER, 2014, 13 (04) : 232 - 238
12345